Brazil to produce Humira biosimilar without Abbott's involvement
This article was originally published in Scrip
Executive Summary
Abbott Laboratories, which last year posted sales of $6.5 billion worth of Humira worldwide, was not involved in what appears to be a technology development deal to produce a biosimilar version of the monoclonal antibody in Brazil.